化合物简介
Dronedarone (development codename SR33589 and marketed as Multaq) is a drug by Sanofi-Aventis, mainly for the indication of cardiac arrhythmias. It was approved by the FDA on July 2, 2009. It was recommended as an alternative to amiodarone for the treatment of atrial fibrillation and atrial flutter in people whose hearts have either returned to normal rhythm or who undergo drug therapy or electric shock treatment i.e. direct current cardioversion (DCCV) to maintain normal rhythm. It is a class III antiarrhythmic drug. In the United States, the FDA approved label includes a claim for reducing hospitalization, but not for reducing mortality, as a reduction in mortality was not demonstrated in the clinical development program. A trial of the drug in heart failure was stopped as an interim analysis showed a possible increase in heart failure deaths, in patients with moderate to severe CHF.
基本信息
中文名称
决奈达隆
英文名称
dronedarone
中文别名
英文别名
Dronedarone、N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide、Multaq、UNII-JQZ1L091Y2
CAS号
141626-36-0
分子式
C31H44N2O5S
分子量
556.756
精确质量
556.297
PSA
97.23
LOGP
8.2028
编号系统
UNII
JQZ1L091Y2
物化性质
密度
1.143 g/cm3
沸点
683.9ºC at 760 mmHg
闪点
367.4ºC
折射率
1.563
蒸汽压
1.47E-18mmHg at 25°C
安全信息
海关编码
3004909090
合成路线
上游原料
共找到133个上游原料 >